As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,850 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
Enabling more than 5,850 Innovative Collaborators from more than 30 Countries
Small Molecule Drug R&D and Manufacturing
Cell Therapy
and Gene Therapy
Drug R&D and Medical
Device Testing
Clinical
Services
Small Molecule Drug R&D and Manufacturing
To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry
WuXi AppTec Reports Record First-Half Results in 2022
WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation
WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility
WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies
WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region
WuXi AppTec Reports Record First-Quarter In 2022
